Oligonucleotide (Antisense oligonucleotide) · Gene silencing: transthyretin (TTR) · developed by Astrazeneca
Eplontersen is an antisense oligonucleotide-GalNAc conjugate that binds TTR mRNA and causes its degradation, lowering serum transthyretin protein and TTR deposits in tissues. It is being studied in transthyretin amyloid cardiomyopathy and is used for the polyneuropathy of hereditary transthyretin-mediated amyloidosis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Apr 15, 2026). Read the full label for the exact wording, limitations and safety information.
Transthyretin Amyloid Cardiomyopathy
Updated Nov 8, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →